当前位置：
X-MOL 学术
›
J. Pediatr. Hematol. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
The Use of Sunitinib as Maintenance Therapy in a Pediatric Patient With a Poorly Differentiated Thymic Carcinoma.
Journal of Pediatric Hematology/Oncology ( IF 0.9 ) Pub Date : 2021-09-06 , DOI: 10.1097/mph.0000000000002312 Eleny Romanos-Sirakis 1, 2 , Andrew Doan 3 , Mark E Bittman 4 , Ryan L Webb 5 , Alex K Williamson 2, 6 , Morris Edelman 2, 6 , Derek Hanson 7 , Gregory J Riely 8 , Carolyn Fein Levy 2, 9
Journal of Pediatric Hematology/Oncology ( IF 0.9 ) Pub Date : 2021-09-06 , DOI: 10.1097/mph.0000000000002312 Eleny Romanos-Sirakis 1, 2 , Andrew Doan 3 , Mark E Bittman 4 , Ryan L Webb 5 , Alex K Williamson 2, 6 , Morris Edelman 2, 6 , Derek Hanson 7 , Gregory J Riely 8 , Carolyn Fein Levy 2, 9
Affiliation
Thymic carcinomas are rare aggressive mediastinal tumors with a median survival of 2 years.
中文翻译：
舒尼替尼作为低分化胸腺癌儿科患者维持治疗的应用。
胸腺癌是罕见的侵袭性纵隔肿瘤，中位生存期为 2 年。
更新日期：2021-09-06
中文翻译：
舒尼替尼作为低分化胸腺癌儿科患者维持治疗的应用。
胸腺癌是罕见的侵袭性纵隔肿瘤，中位生存期为 2 年。
京公网安备 11010802027423号